Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances

Jonathan Riess, Heather A. Wakelee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume10
Issue number4
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Histology
Mutation
Oncogenes
Developed Countries
Lung Neoplasms
Adenocarcinoma
Epithelial Cells
Clinical Trials
Mortality
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Clinical trials
  • Molecular markers
  • Non-small cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Metastatic non-small cell lung cancer management : Novel targets and recent clinical advances. / Riess, Jonathan; Wakelee, Heather A.

In: Clinical Advances in Hematology and Oncology, Vol. 10, No. 4, 04.2012, p. 226-234.

Research output: Contribution to journalArticle

@article{4a4985167cfb43d3a79c19ac4641d45e,
title = "Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances",
abstract = "Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.",
keywords = "Chemotherapy, Clinical trials, Molecular markers, Non-small cell lung cancer, Targeted therapy",
author = "Jonathan Riess and Wakelee, {Heather A.}",
year = "2012",
month = "4",
language = "English (US)",
volume = "10",
pages = "226--234",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "4",

}

TY - JOUR

T1 - Metastatic non-small cell lung cancer management

T2 - Novel targets and recent clinical advances

AU - Riess, Jonathan

AU - Wakelee, Heather A.

PY - 2012/4

Y1 - 2012/4

N2 - Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.

AB - Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.

KW - Chemotherapy

KW - Clinical trials

KW - Molecular markers

KW - Non-small cell lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84859642825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859642825&partnerID=8YFLogxK

M3 - Article

C2 - 22706483

AN - SCOPUS:84859642825

VL - 10

SP - 226

EP - 234

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 4

ER -